GlassScriptPhysician profile
Aisha Khan
NPI 1871270751
$1,154.83
in general payments reported to CMS, 2019-2025
20 companies · $878 in 2025
The $878 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $277 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $201.34 | 2024-2025 | |
| Novo Nordisk INC | $145.36 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $115.02 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $107.18 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $103.30 | 2024-2025 | |
| Glaxosmithkline, LLC. | $63.36 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $62.68 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $54.85 | 2025 | Farxiga, Airsupra |
| Dexcom, INC. | $45.22 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.85 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.52 | 2025 | Ofev, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.66 | 2024-2025 | Xifaxan |
| Insmed, INC. | $24.98 | 2025 | Arikayce |
| Azurity Pharmaceuticals, INC. | $22.42 | 2025 | Edarbi |
| Merck Sharp & Dohme LLC | $21.10 | 2025 | Gardasil 9, Capvaxive |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $16.70 | 2025 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $15.40 | 2025 | Rexulti |
| Amgen INC. | $13.86 | 2025 | Otezla, Repatha |
| Phadia US INC. | $13.81 | 2025 | Immunocap |
| Lilly USA, LLC | $13.22 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.